Although the remaining three genes, PMVK, MVD, and SC5D are currently not targets of existing drugs, they are all related to the main-effect pathway cholesterol biosynthesis and important for tumorigenesis of HCC, which might become novel potential therapeutic targets and worthy of exploration in future studies. Here, PMVK is linked to hepatocellular carcinoma.